Akums Q1 FY27 Revenue up 13.9% to ₹1,167 Cr; Acquires Oriflame India Biz for ₹56 Cr
Akums reported Q1 FY27 revenue of ₹1,167 crore, up 13.9% YoY, with EBITDA at ₹175 crore, up 35.4%. The company acquired Oriflame India's manufacturing business for ₹56 crore. CDMO segment drove growth. Investor presentation for the call on August 10, 2026, is available.
The substantial revenue growth, improved profitability, and a strategic acquisition of a manufacturing business are significant positive developments for the company.
The company reported strong year-on-year growth in revenue and EBITDA, along with a significant strategic acquisition that expands its market presence.
Akums Drugs and Pharmaceuticals Limited has announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), reporting a significant revenue growth of 13.9% year-on-year, reaching ₹1,167 crore. The company's EBITDA also saw a substantial increase of 35.4% to ₹175 crore, with an improved EBITDA margin of 15.0% compared to 12.6% in the previous year.
The growth was primarily driven by the CDMO segment, which contributed 82.6% to the revenue and exhibited double-digit volume growth. The API segment continued its progress towards EBITDA positivity, benefiting from a higher share of non-cephalosporin products and improved gross margins. The trade generics segment remained EBITDA positive.
Akums' domestic branded formulations segment showed a healthy revenue growth of 7%, though margins were impacted by increased field force strength. The international branded formulations business had a muted quarter but is expected to recover. The company also announced the acquisition of Oriflame India's manufacturing business for ₹56 crore, which includes two manufacturing facilities and a leased warehouse. This strategic move expands Akums' footprint in skincare, cosmetics, and wellness products, aligning with its strategy to tap into niche formulations and improve margins.
Looking ahead, the company expressed confidence in creating long-term shareholder value. A copy of the investor presentation for the Q1 FY27 earnings conference call, scheduled for August 10, 2026, has been enclosed.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.